Background
The recent years have witnessed a rising trend in the number of young acute ischemic stroke patients who are under 45 years old, leading to increasing social and economic burdens. Reperfusion therapies, including intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT), are effective treatment methods.
Aims
This study aimed to evaluate the clinical outcome among young acute ischemic stroke patients who received reperfusion therapies at the Bachmai Stroke Center.
Methods
A prospective cross-sectional study was conducted at Bachmai Stroke Center. All acute ischemic stroke patients under 45 years of age who received reperfusion therapies from August 2021 to July 2022 were enrolled. The main result was the proportion of good clinical outcomes (mRS 0-2) at 90 days. Multivariate regression analysis was used to point out predictors of good clinical outcomes.
Results
51 patients (mean age: 38.0 ± 5.9, male 68.4%) were recruited. At admission, the median NIHSS score was 8 (4-12). Thrombectomy treatments accounted for 70.6% (of whom 17.6% received combined therapies). Median door-to-needle and door-to-groin puncture times were 21,7±10,3 and 82,6±28,4 minutes, respectively. Successful revascularization (mTICI ≥ 2b) was achieved in all EVT patients. Symptomatic transformation hemorrhage was 14%.
At 90 days, 82.4% of patients achieved good outcomes (mRS 0-2) and 5.3% died. Multivariate regression analysis revealed 3 factors associated with good clinical outcomes, including shorter door-to-needle and door-to-groin-puncture times, and absence of symptomatic intracranial hemorrhage.
Conclusion
This study showed a high rate of favorable outcomes among young acute ischemic stroke patients receiving reperfusion treatment at Bachmai Stroke Center.